Paper test strip allows heart failure patients to monitor disease at home

The nearly six million people living with heart failure face a life of monitoring the disease in the event it worsens. This often involves traveling to a physician on a routine basis, but scientists have opened an avenue to in-home monitoring with a simple paper test strip.

To cut costs and increase patient’s engagement, scientists developed an at-home paper strip test to identify the antigens responsible for indicating progressive heart failure. The findings were published in ACS Nano.

The antigens, ST2 and BNP, are currently only identified by trained professionals with complex lab equipment. The paper strip test gives patients the ability to take control of their disease monitoring by including all aspects of analysis in an at-home test.

The test uses a 10 microliters sample of blood, with the strip glowing blue when detecting ST2 and green with detecting BNP. The stronger the concentration of antibodies means a more intense color, meaning a user is more likely heart failure to be progressing. Patients can then use the accompanying smartphone application to analyze information and send results to their physician, who can direct the patient in adjusting their medication dosage.

In 38 serum samples, the test could detect minimal concentrations of ST2 and BNP. These results were compared to U.S. Food and Drug Administration clinical methods to show a linear correlation for the reliability and stability of the test.

“Therefore, the developed UC-LFS platform is demonstrated to be highly sensitive and specific for sample-to-answer prognosis of HF, which holds great potential for risk assessment and health monitoring of post-treatment patients at home,” concluded first author Feng Xu and colleagues.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.